O. Khan
Mayo Clinic
3 Papers
4 Citations
O. Khan is an academic researcher from Mayo Clinic. The author has contributed to research in topics: Internal medicine & Renal cell carcinoma. The author has an hindex of 1, co-authored 1 publications.
Chat about Author
Papers
Temporary treatment cessation versus continuation of first-line tyrosine kinase inhibitor in patients with advanced clear cell renal cell carcinoma (STAR): an open-label, non-inferiority, randomised, controlled, phase 2/3 trial.
Janet E. Brown,Kara-Louise Royle,Walter M Gregory,Christy Ralph,Anthony Maraveyas,O.S. Din,Tim Eisen,Paul Nathan,Thomas Powles,Richard Griffiths,Robert Jones,Naveen S. Vasudev,Matthew Wheater,A. Hamid,T. Waddell,Rhona McMenemin,Poulam M. Patel,James Larkin,Guy Faust,Jayne Swain,Janine C Bestall,Christopher McCabe,David M. Meads,Vicky Goh,Tze Min Wah,Julia Brown,Jenny Hewison,Peter Selby,Fiona Collinson,Judith E. Carser,Gopalakrishnan Srinivasan,Fiona Thistlewaite,Ashraf Azzabi,Mark Beresford,David Farrugia,Marios P. Decatris,Carys Thomas,Joanna Gale,J. J. McAleer,A. Clayton,Ekaterini Boleti,T. Geldart,Santhanam Sundar,Jason F. Lester,Nachi Palaniappan,Mohan Hingorani,Khaliqur Rehman,Mohammad Emrul Hasan Khan,Naveed Sarwar,Janine Graham,Alastair M. Thomson,Narayanan Srihari,D. Sheehan,Rajaguru Srinivasan,O. Khan,Andrew Stockdale Jane Worlding,Stergios Boussios,N Stuart,Carey F MacDonald-Smith,F. Danwata,Duncan McLaren,Aravindhan Sundaramurthy,Anna Lydon,Sharon Beesley,Kathryn Lees,Mohini Varughese,Emma Gray,Angela Scott,Mark Baxter,Anna Mullard,Pasquale F. Innominato,Gaurav Kapur,Ashok Kumar,Natalie Charnley,C. Manetta,Prabir Chakraborti,Prantik Das,Sarah Rudman,H. Taylor,Christos Mikropoulos,Martin Highley,D Muthukumar,Anjali Zarkar,Roy Vergis,Seshadri Sriprasad,P. Brulinski,Amanda Clarke,R.D. Osbourne,Melanie Harvey,Renata Dega,G. Sparrow,Urmila Barthakur,E. Beaumont,Agnieszka Michael,Emilio Porfiri,Faisal Azam,Ravi Kodavtiganti +96 more
TL;DR: In this article , the authors compared a drug-free interval strategy with a conventional continuation strategy for first-line treatment of advanced clear cell renal cell carcinoma (CRC) patients.
37
LBA66 IMmotion010: Efficacy and safety from the phase III study of atezolizumab (atezo) vs placebo (pbo) as adjuvant therapy in patients with renal cell carcinoma (RCC) at increased risk of recurrence after resection
Alex Bex,Robert G. Uzzo,Jose A. Karam,V. Master,Frede Donskov,Cristina Sáez,Laurence Albiges,B. I. Rini,Yoshihiko Tomita,Ariel Galapo Kann,Giuseppe Procopio,Federico Massari,Matthew Zibelman,Igor Antonyan,Mahrukh Huseni,Diya Basu,Bo Ci,W. Leung,O. Khan,S. K. Pal +19 more
TL;DR: The authors evaluated atezo (anti-PD-L1) monotherapy as adjuvant therapy in loco-regional RCC and increased risk of recurrence after resection.
23
Metastatic lung adenocarcinoma in a 20-year-old patient.
O. Khan,W.P. Tong,N.J. Karlin +2 more
TL;DR: The unique challenges in diagnosing and treating young patients with metastatic lung cancer are illustrated with a 20-year-old man with no history of tobacco use who complained of several months of cough and lower back pain and an 11.3-kg weight loss.
4